Anti-Ma2 Paraneoplastic Encephalitis and Testicular Cancer: When the Hypothalamus Whispers-A Case Report and Systematic Review with Emphasis on Hypothalamic-Endocrine Dysfunction.

Virginia Zamponi, Piero Paravani, Rossella Mazzilli, Flaminia Russo, Marina Paola Gardiman, Bruno Giometto, Raffaele Iorio, Alessandro Peri, Marco Zoccarato, Antongiulio Faggiano

Journal: Medical sciences (Basel, Switzerland) 2026;14(2):

PMID: 42029599

Abstract

Background: Paraneoplastic limbic encephalitis (PLE) with anti-Ma2 antibodies is a rare immune-mediated disorder associated with testicular cancer, particularly in young males. While neurological manifestations are well documented, hypothalamic-pituitary dysfunctions remain underreported. We present a case of anti-Ma2 PLE associated with testicular cancer together with a systematic review of PLE associated with testicular cancer, selectively restricted to anti-Ma2 positive cases and focusing on hypothalamic-endocrine involvement. Case presentation: We describe a 21-year-old male diagnosed with anti-Ma2 PLE and intratubular germ cell neoplasia of the right testis. He underwent orchifunicolectomy and immunosuppressive therapy with neurological improvement. Four years later, he developed new-onset temporal seizures, decreased libido, and a polyuria-polydipsia syndrome. Dynamic endocrine testing, including a water deprivation test and copeptin measurement, supported a diagnosis of partial central diabetes insipidus (CDI). Methods: A systematic literature review was performed in accordance with PRISMA guidelines. PubMed was searched using predefined keywords without time restriction. Studies reporting PLE associated with testicular tumors in humans with confirmed anti-Ma2 antibody positivity were included. Results: Eleven studies were included, reporting a total of 38 patients with anti-Ma2-associated PLE and testicular cancer. Hypothalamic or diencephalic involvement was described in 16 patients (42.0%), while endocrine manifestations were explicitly reported in four cases. Only two previous reports mentioned CDI, without detailed diagnostic evaluation. Conclusions: This study highlights the importance of recognizing hypothalamic-endocrine manifestations in PLE. In patients presenting with polydipsia and polyuria, CDI should be carefully differentiated from primary polydipsia using dynamic testing. Hypothalamic involvement may emerge years after tumor treatment, warranting long-term endocrine surveillance.

Address: Endocrinology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.; Surgical Pathology and Cytopathology Unit, Department of Medicine, University of Padua, 35122 Padua, Italy.; Neurology Unit, Hospital of Trento, Azienda Provinciale per i Servizi Sanitari-APSS, 38122 Trento, Italy.; Department of Neuroscience, Università Cattolica del Sacro Cuore, 38122 Rome, Italy.; Pituitary Diseases and Sodium Alterations Unit, Endocrinology, Careggi University Hospital, University of Florence, 50121 Florence, Italy.; Neurology Unit, Ospedale Sant'Antonio, Azienda Ospedale Università di Padova, 35128 Padua, Italy.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.